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Abstract
Background: Once ingested, dioxins and dioxin-like compounds are excreted extremely slowly. Excretion can be
evaluated by its half-life. Half-lives estimated from observed concentrations are affected by excretion and ongoing
exposure. We investigated the change in apparent half-life using a theoretical model based on exposure to dioxin
and dioxin-like compounds.
Methods: We carried out longitudinal measurements of the blood concentration of dioxins and dioxin-like
compounds in a Yusho cohort during 2002 to 2010. We estimated the change in decay rates of 2,3,4,7,8-
PeCDF and octachlorodibenzodioxin (OCDD) using a second-order equation.
Results: We found that the decay rate of OCDD increased, whereas the decay rate of 2,3,4,7,8-PeCDF of
patients with a relatively high concentration of 2,3,4,7,8-PeCDF decreased. OCDD results were in accordance
with decreasing levels of dioxin and dioxin-like compounds in the environment. The decay rate of OCDD in
the body was affected by the decay rate of OCDD in the environment by ingestion because it was near the
steady-state. In contrast, the decay rate of 2,3,4,7,8-PeCDF in the body was affected less by ingestion from the
environment because it was far higher than in the steady-state.
Conclusion: We demonstrated that the level of 2,3,4,7,8-PeCDF in the environment is decreasing. The excretion half-life
is longer than the environmental half-life, thus the excretion half-life in a Yusho patient is increased.
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Background
Yusho refers to a mass food poisoning that occurred in
western Japan in 1968. Early studies indicated that Yusho
was caused by polychlorinated biphenyls (PCBs). Accord-
ing to a number of subsequent studies, though, it is now
accepted that 2,3,4,7,8-pentachlorodibenzofuran (PeCDF)
was the main causative compound of Yusho [1, 2]. The
concentrations of dioxins and dioxin-like compounds in
the blood of Yusho patients have been measured at annual
medical checkups since 2001 [3, 4].
Once ingested, dioxins and dioxin-like compounds are
excreted extremely slowly. Given their health implications,
there has been a great deal of interest in the half-lives of
these compounds in humans. In patients with high blood
concentrations of dioxin-like compounds, half-lives of
1.1 years have been reported, increasing to 7.2 years in pa-
tients with low blood concentrations [5]. Other estimates
on half-lives of dioxin-like compound include 8.9 years by
Masuda et al. [6], 9.6 years by Ryan et al. [7] and 9.1 years
by Iida et al. [8]. Many researchers have reported half-lives
of PCBs to be less than 10 to 15 years [9, 10]. Among
patients with blood concentrations of 2,3,4,7,8-pentachlor-
odibenzofuran (2,3,4,7,8-PeCDF) ≥50 pg/g lipid, we identi-
fied two groups: one showing an apparent half-life of ≈
10 years and the other showing no reduction in 2,3,4,7,8-
PeCDF levels over time [11]. This suggests that the latter
group of patients maintained high blood levels of
2,3,4,7,8-PeCDF.
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Since the medical checkups began, the group having a
2,3,4,7,8-PeCDF apparent half-life of around 10 years
became smaller while the group having a near infinite
apparent half-life became larger [12]. Therefore, the ex-
cretion half-life changed in individual patients. Milbrath
et al. [13] pointed out that excretion half-life was af-
fected by menopause, and other researchers reported
that those changes in apparent half-lives were affected
by intake [14]. In this paper we evaluate the changes in
apparent half-life of dioxin-like compounds.
Methods
The subjects were 354 patients whose blood concentra-
tion of 2,3,4,7,8-PeCDF had been measured three or
more times at annual Yusho medical checkups between
2002 and 2010, i.e., 34–42 years since exposure, and for
whom the period from the first to last measurement was
over 4 years. We examined two chemicals: 2,3,4,7,8-
PeCDF, which is the causative chemical [2], and octa-
chlorodibenzodioxin (OCDD), which is a chemical found
in Yusho patients but less commonly in the general public
[15]. Patient distribution according to 2,3,4,7,8-PeCDF
concentration in 2006 (middle of the observation period)
is shown in Table 1. This research was approved by Nara
Medical University Ethics Committee (No. 281–2).
The excretion of dioxins and dioxin-like compounds is
proportional to body burden. If there is no intake of these
compounds and their quantity decreases in proportion to
body burden then their decay will be logarithmic. How-
ever, body burden of dioxins and dioxin-like compounds
is affected by intake as well as excretion. Therefore, the
body burden itself will not decay logarithmically.
Time course curves can be characterized by second-
order differentiation. Figure 1(a) shows a linear curve
with a positive gradient; the first derivative is positive
and the second derivative is zero. Likewise, Fig. 1(b)
shows a linearly decreasing curve with negative first de-
rivative and zero second derivative. Curves with non-
zero second derivatives are shown in Fig. 1(c) and (d);
the former curve is concave with positive second deriva-
tive, and the latter is convex with negative second de-
rivative. The rate of change in body burden is expressed
by its second-order derivative with respect to time.
For the logarithm of body burden, which was calcu-
lated from concentration and weight, we examined the
second derivative by second-order regression. The body
burden Cit of patient i at time t is given by:
logCit ¼ βi þ α1t þ α2t2 þ γ1w1it þ γ2w2it ð1Þ
where t is the time, with t = 0 denoting 2006 (middle
of the observation period), α2 is the coefficient for a
second-order derivative, α1 is the first-order derivative at
time t = 0, βi is the reference value for each individual,
W1it is the weight and W2it is the lipid in blood (%) of
patient i at time t, and γj is the coefficient for weight
and lipid in blood. Aylward et al. used an estimate of
body fat as volume of distribution [16], but we used
weight and lipid in blood.
We combined all observed concentrations into equa-
tion (2):
y ¼ X⋅βþ T ⋅αþW ⋅γ þ ε ð2Þ
where y is the vector of the logarithm of dioxins and
dioxin-like compounds in blood lipid concentration, Xβ
is the base concentration for each patient, Tα is the
change in time, Wγ is an adjustment term according to
weight and lipid in blood, and ε is an observation error.
X is a matrix with the total number of measurements
rows and number of patient columns. T is a matrix with
the total number of measurement rows and two col-
umns, second-order and first-order for time. W is the
matrix with the total number of measurement rows and
two columns, weight and lipid. Equation (3) is a matrix
form:








By solving multiple linear regressions with the lm
function in R, we could estimate first- and second-order
derivatives. It was assumed that patients in the same
group had same trend with regard to time. Conversely, it
was assumed that patients in different groups had a dif-
ferent trend with respect to time. For the case of one pa-
tient and no second-order coefficient measurements,
equation (3) equals leads to an equation for estimation
of decay rate:
ka ¼ lnCt2− lnCt1
Δt
: ð4Þ
The governing equation for a one-compartment PK
model having a constant intake and an excretion propor-
tional to body burden is
dQ
dt
¼ −λ⋅Qþ I: ð5Þ
By integrating Eq. (5) we obtain the body burden as a
function of time,
Table 1 Distribution of 2,3,4,7,8-PeCDF concentration
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Q0 is a constant of integration corresponding to time








Q tð Þ ¼ − 1
Q tð Þ λ⋅Q−Ið Þ; ð7Þ
and taking a second derivative gives
d2
dt2
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logQ tð Þ: ð9Þ
We estimated the first- and second-order coefficients,
equivalent to the decay rate and change in decay rate,
for OCDD and 2,3,4,7,8-PeCDF for each patient group
shown in Table 1.
Results
Figure 2 shows the time progression of body burden
with a constant intake of dioxins for initially high and
low concentrations, governed by Eq. (5). The dashed line
corresponds to the steady-state of the body burden being
equal to the integration constant, Q(t) =Q0. In a patient
who underwent accidental exposure to a high level of di-
oxins, the body burden will decay exponentially as the
first derivative is negative. In a patient who has a lower
body burden than the steady-state level, the body burden
will approach the steady-state level in an exponential
a b
c b
Fig. 1 Linear and parabolic curves. a First derivative is positive and second derivative is zero; (b) first derivative is negative and second derivative
is zero; (c) second derivative is positive; (d) second derivative is negative
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fashion; i.e., the first derivative is positive and the second
derivative is negative. Bartell evaluated how intake af-
fects half-life if intake is constant [14].
Table 2 shows the coefficients and p-values for
2,3,4,7,8-PeCDF body burden. The second-order coeffi-
cients for patients who have 2,3,4,7,8-PeCDF concentra-
tions greater than 50 pg/g lipid are positive; i.e., the
curves are concave. For patients who have less than
50 pg/g lipid, the p-values are higher than 5 %. The coef-
ficient for second-order derivative is not determined, i.e.,
the curve is linear. The first-order coefficients are nega-
tive for patient concentrations greater than 50 pg/g lipid.
For concentrations <50 pg/g lipid, p > 0.05 (i.e., was not
significant), so the coefficient for the first-order deriva-
tive would not change the body burden. Only the group
with a lipid concentration >50 pg/g had a negative ap-
parent rate of change in concentration. Figure 3 shows
the estimated time trend curve and typical changes for 4
patients with a high concentration of 2,3,4,7,8-PeCDF.
Table 3 presents the coefficients and p-values for
OCDD body burden. All second-order coefficients for all
concentration groups were negative and p < 0.05 %, so
the curves were convex. First-order coefficients were
negative and p < 0.05 % for all concentrations groups, so
the change in OCDD concentration was negative (i.e.,
OCDD concentration was declining).
Discussion
In Japan, young people have lower concentrations of
2,3,4,7,8-PeCDF than older people [17, 18]. The model
in which the environmental concentration is decreasing
is the more realistic model. If intake is constant, older
people may have a higher concentration than that in
young people due to accumulation of dioxin and dioxin-
like compounds. However, in this model, if the concen-
tration is near steady-state, the rate of increase is slowed
down. If the concentration in the environment is
decreasing, body burden is decreased because of a total
decrease in exposure from birth. The production of di-
oxins was restricted in the 1970s and concentrations of
dioxins and dioxin-like compounds in the environment
subsequently fell. Thus, the intake of these compounds
is no longer constant. Some scholars have reported that
levels of dioxins and dioxin-like compounds in the envir-
onment have decreased [10, 19, 20].
Let us assume that the intake is decreasing according
to the following equation,
I tð Þ ¼ I0⋅e−λ0⋅t : ð10Þ
We combine Eq. (5) and Eq. (10) to get
dQ
dt
¼ −λ⋅Qþ I0⋅e−λ0⋅t : ð11Þ
Integrating Eq. (11) gives body burden as a function of
time,
Q tð Þ ¼ I0
λ−λ0
⋅e λ−λ0ð Þ⋅t þ Q0
 
⋅e−λ⋅t : ð12Þ
Figure 4 plots body burden with a decreasing intake
for patients with initially high and low concentrations
and a patient at steady-state. In the patient with initially
Fig. 2 Change in body burden in the constant-intake model
Table 2 Apparent elimination rate and change in elimination




minus change in apparent




coefficient p-value coefficient p-value
0–10 −0.000596 0.599665 −0.004032 0.165814
10–20 0.000464 0.463854 −0.000462 0.786707
20–50 0.000643 0.182574 0.001669 0.229181
50–100 0.002124 7.99 × 10−5 −0.005452 0.000216
>100 0.001436 9.68 × 10−7 −0.008294 <2 × 10−16
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high concentration, the body burden decays exponen-
tially at an ever-slower rate. Thus, the second derivative
is positive. In the patient with initially low concentration,
the body burden increases then decreases, which corre-
sponds to polarity changes in the first derivative and
negative second derivative throughout.
2,3,4,7,8-PeCDF is a causative compound of Yusho.
Yusho patients have a higher concentration of 2,3,4,7,8-
PeCDF than do the general public. Yusho patients have
a lower concentration of OCDD than do the general
public [15].
In the OCDD results in Table 3, the first- and second-
order differentiation coefficients are negative. The OCDD
concentration was a convex curve. Yusho patients had a
lower concentration of OCDD than do the general public,
and the body burden approached the steady-state. If the
body burden was approaching but not yet at steady-state
and the OCDD environmental level was reducing faster
than the body excretion rate, then the first and second
derivatives would be negative. Ritter et al. [19] estimated
the excretion half-life of dioxins from measurements of
people at one time point using a model that assumed a de-
creasing level of dioxins in the environment. These find-
ings are not in accordance with the constant-intake
model. OCDD data were in accordance with the hypoth-
esis of decreasing levels of dioxins and dioxin-like com-
pounds in the environment.
Results for 2,3,4,7,8-PeCDF summarized in Table 2 are
consistent with those shown in Fig. 2 for a patient group
having >50 pg/g lipid; second derivatives were positive
and the first derivatives were negative, and a concave
curve was produced. In the group having less than
50 pg/g lipid, the p-values are higher than 5 %, and the
sign of the coefficients cannot not be determined
because body burden is low, intake and excretion have
similar values and there are substantial differences
between patients.
Therefore, to accurately predict body burden, a model
should assume a decreasing level of 2,3,4,7,8-PeCDF. The
decrease in intake will be influenced directly. If decay in
the environment occurs at a constant rate and the envir-
onment half-life is longer than the excretion half-life, then
the apparent half-life converges to the environment half-
life [21]. The variation of ingestion does not affect the
converged reduction rate. In the 2,3,4,7,8-PeCDF results,
however, there is no decrease in the concentration for pa-
tients having less than 50 pg/g lipid. If the environment
half-life is shorter than the excretion half-life, then the ap-
parent half-life converges to the excretion half-life, and
the second derivative is negative. This hypothesis is not in
accordance with 2,3,4,7,8-PeCDF results.
Fig. 3 Trend for 4 typical patients and estimation of a curve for a high concentration
Table 3 Apparent elimination rate and change in elimination




minus change in apparent




coefficient p-value coefficient p-value
0–10 −0.006366 4.80 × 10−7 −0.014329 7.87 × 10−6
10–20 −0.003289 5.81 × 10−5 −0.019541 <2 × 10−16
20–50 −0.001897 0.006100 −0.020541 <2 × 10−16
50–100 −0.002991 0.003593 −0.012243 2.04 × 10−5
>100 −0.004341 <2 × 10−16 −0.009034 2.94 × 10−9
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We reported that concentrations of 2,3,4,7,8-PeCDF in
Yusho patients are decreasing very slowly and prolong-
ing the apparent half-life [12]. With a decreasing con-
centration in the environment and a constant excretion
half-life, the apparent half-life of high concentrations is
shortening. Our report is inconsistent with the constant
excretion model. The prolongation of the apparent half-
lives of 2,3,4,7,8-PeCDF at high concentrations is caused
by the prolonging of excretion half-lives.
Conclusions
If a person is exposed to high levels of dioxins and
dioxin-like compounds in the environment and if excre-
tion half-life is shorter than the environmental half-life,
then the apparent half-life will be more profoundly influ-
enced by to the environmental half-life. Conversely, if
the excretion half-life is longer than the environmental
half-life, then the apparent half-life will be preferentially
influenced by the excretion half-life. We demonstrated
that the level of 2,3,4,7,8-PeCDF in the environment is
decreasing. Our results show that the excretion half-life
is longer than the environmental half-life, thus the
excretion half-life in a Yusho patient is increasing.
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